Revolutionary Hypertension Treatment

Arterial hypertension is the most important cardiovascular risk factor affecting more than 1.2 billion people worldwide.¹

Arterial hypertension is responsible for most cardiovascular complications (non-fatal and fatal).²

¹ Mancia G, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023 Dec 1;41(12):1874-2071.

² GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1223-1249.

Current Renal Ablation with radiofrequency or ultrasonic heat falls short on outcomes, achieving at most 10 mmHg systolic blood pressure reduction.³

³ Barbato E, et al. Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2023 Apr 17;44(15):1313-1330.

Cryovasc is the first to apply low-risk but highly effective cryoablation technology for catheter-based renal denervation to treat arterial hypertension.

With our product, sympathetic nerves can be ablated comprehensively, as the procedure is endpoint-controlled, i.e. renal denervation can be applied, until the nerves are fully interrupted.

The cryoablation procedure is associated with very low risks of causing damage as compared to heat damage from the currently available radiofrequency or ultrasound renal denervation technologies.

Preclinical proof-of-principle is successfully completed and the manuscript is submitted to a high impact factor journal.